In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Pharma's Practice-Changing Data Dominates At ESMO

Executive Summary

Unseasonal showers hit Madrid during the European Society for Medical Oncology congress where most of the major data readouts came from the biggest players in the sector rather than ambitious biotechs. Here, In Vivo looks at three must-see presentations from the prestigious meeting.

You may also be interested in...

ESMO 2023: TROPION-Breast01 And -Lung01 Studies Breathe Life Into Dato-DXd

The future for AstraZeneca/Daiichi Sankyo’s TROP2-targeted ADC candidate Dato-DXd is looking more positive after details of their TROPION-Lung01 and TROPION-Breast01 Phase III studies were presented at ESMO.

ESMO 2023: Will J&J’s Rybrevant Be Able To Scale The Tagrisso Mountain?

Scrip talked to Johnson & Johnson’s vice president of oncology global medical affairs, Mark Wildgust, about how the healthcare giant hopes to plant a flag on Tagrisso’s mountain with its trio of Phase III butterfly-themed studies for the bispecific antibody Rybrevant presented at ESMO.

ESMO 23: Madrid Meeting Hails Padcev/Keytruda Combo As New Bladder Cancer Standard Of Care

The combination of Astellas and Seagen's antibody-drug conjugate Padcev and Merck & Co's checkpoint inhibitor  Keytruda has shown improvements in survival not previously achieved in a broad population of patients with advanced urothelial carcinoma.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts